Immage Total Assets from 2010 to 2026
| IMMG Stock | USD 0.0001 0.00 0.00% |
Total Assets | First Reported 2010-12-31 | Previous Quarter 279.6 K | Current Value 293.5 K | Quarterly Volatility 110 K |
Check Immage Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immage Biotherapeutics' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 0.0 or Selling General Administrative of 186.3 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 7.0E-4. Immage financial statements analysis is a perfect complement when working with Immage Biotherapeutics Valuation or Volatility modules.
Immage | Total Assets | Build AI portfolio with Immage Stock |
Latest Immage Biotherapeutics' Total Assets Growth Pattern
Below is the plot of the Total Assets of Immage Biotherapeutics Corp over the last few years. Total assets refers to the total amount of Immage Biotherapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Immage Biotherapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Immage Biotherapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immage Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 243.1 K | 10 Years Trend |
|
Total Assets |
| Timeline |
Immage Total Assets Regression Statistics
| Arithmetic Mean | 182,842 | |
| Geometric Mean | 94,988 | |
| Coefficient Of Variation | 60.16 | |
| Mean Deviation | 95,301 | |
| Median | 243,104 | |
| Standard Deviation | 109,996 | |
| Sample Variance | 12.1B | |
| Range | 291.2K | |
| R-Value | 0.84 | |
| Mean Square Error | 3.8B | |
| R-Squared | 0.71 | |
| Significance | 0.000024 | |
| Slope | 18,304 | |
| Total Sum of Squares | 193.6B |
Immage Total Assets History
Other Fundumenentals of Immage Biotherapeutics
Immage Biotherapeutics Total Assets component correlations
Click cells to compare fundamentals
About Immage Biotherapeutics Financial Statements
Immage Biotherapeutics stakeholders use historical fundamental indicators, such as Immage Biotherapeutics' Total Assets, to determine how well the company is positioned to perform in the future. Although Immage Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Immage Biotherapeutics' assets and liabilities are reflected in the revenues and expenses on Immage Biotherapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Immage Biotherapeutics Corp. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Assets | 279.6 K | 293.5 K | |
| Intangibles To Total Assets | 0.02 | 0.02 |
Currently Active Assets on Macroaxis
When determining whether Immage Biotherapeutics is a strong investment it is important to analyze Immage Biotherapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Immage Biotherapeutics' future performance. For an informed investment choice regarding Immage Stock, refer to the following important reports:Check out the analysis of Immage Biotherapeutics Correlation against competitors. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immage Biotherapeutics. If investors know Immage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immage Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immage Biotherapeutics is measured differently than its book value, which is the value of Immage that is recorded on the company's balance sheet. Investors also form their own opinion of Immage Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Immage Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immage Biotherapeutics' market value can be influenced by many factors that don't directly affect Immage Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immage Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immage Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immage Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.